Literature DB >> 2038750

Differential DNA-protein crosslinking in lymphocytes and liver following chronic drinking water exposure of rats to potassium chromate.

T P Coogan1, J Motz, C A Snyder, K S Squibb, M Costa.   

Abstract

Carcinogenic chromium (VI) compounds are persistent environmental contaminants with potential for human exposure through drinking water. One lesion associated with chromium (VI) exposure is the formation of DNA-protein crosslinks (DPC). In an attempt to develop markers of chromium exposure, the formation of DPC in lymphocytes was investigated. Fisher 344 rats were exposed to K2CrO4 in their drinking water for 3 and 6 weeks at concentrations of 100 and 200 ppm chromium. No DPC could be detected in isolated splenic lymphocytes using the alkaline elution technique or by using a polyclonal antibody to chromate-induced DPC. However, increased complexing of proteins with DNA was demonstrated in liver following 3 weeks of exposure at both 100 and 200 ppm chromium. Intraperitoneal administration of potassium chromate did not induce detectable DPC in lymphocytes; however, an increased association of proteins with isolated DNA was detected in the liver. DPC were also induced in isolated splenic lymphocytes following a 2-hr exposure in vitro to 100 microM K2CrO4 in a salts-glucose medium. Although chromium was detected in blood, liver, and kidney, blood levels were comparatively much lower. A comparison of chromium levels required to induce DPC in lymphocytes in vitro and the amount absorbed orally suggests that the white blood cell chromium levels following oral exposure may be too low to induce measurable DNA-protein crosslinks in lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2038750     DOI: 10.1016/0041-008x(91)90191-g

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  8 in total

1.  Exposure to hexavalent chromium resulted in significantly higher tissue chromium burden compared with trivalent chromium following similar oral doses to male F344/N rats and female B6C3F1 mice.

Authors:  Bradley J Collins; Matthew D Stout; Keith E Levine; Grace E Kissling; Ronald L Melnick; Timothy R Fennell; Ramsey Walden; Kamal Abdo; John B Pritchard; Reshan A Fernando; Leo T Burka; Michelle J Hooth
Journal:  Toxicol Sci       Date:  2010-09-15       Impact factor: 4.849

Review 2.  Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans.

Authors:  Chad M Thompson; Deborah M Proctor; Mina Suh; Laurie C Haws; Christopher R Kirman; Mark A Harris
Journal:  Crit Rev Toxicol       Date:  2013-03       Impact factor: 5.635

3.  The interaction of the orthopaedic metals, chromium VI and nickel, with hepatocytes.

Authors:  M Gunaratnam; M H Grant
Journal:  J Mater Sci Mater Med       Date:  2001 Oct-Dec       Impact factor: 3.896

Review 4.  Oral Chromium Exposure and Toxicity.

Authors:  Hong Sun; Jason Brocato; Max Costa
Journal:  Curr Environ Health Rep       Date:  2015-09

Review 5.  Application of the U.S. EPA mode of action Framework for purposes of guiding future research: a case study involving the oral carcinogenicity of hexavalent chromium.

Authors:  Chad M Thompson; Laurie C Haws; Mark A Harris; Nicole M Gatto; Deborah M Proctor
Journal:  Toxicol Sci       Date:  2010-10-14       Impact factor: 4.849

6.  DNA-protein cross-links as a biomarker of Cr(VI) exposure.

Authors:  D J Paustenbach; B L Finley
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

7.  Utilization of DNA-protein cross-links as a biomarker of chromium exposure.

Authors:  A Zhitkovich; V Voitkun; T Kluz; M Costa
Journal:  Environ Health Perspect       Date:  1998-08       Impact factor: 9.031

Review 8.  Cytogenomics of hexavalent chromium (Cr 6+) exposed cells: a comprehensive review.

Authors:  Akanksha Nigam; Shivam Priya; Preeti Bajpai; Sushil Kumar
Journal:  Indian J Med Res       Date:  2014-03       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.